To determine the driver of the survival benefit between PD-L1 and CD8, we evaluated the low and high CD8 within each of the tumor PD-L1 < 5% and the tumor PD-L1 ≥ 5% groups; and we did not find a statistically significant difference in OS between these subsets (Figure 4A). Here, CD8A is linked to neoplasm.